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Abstract
Background: Current guidelines recommend assessing and relieving pain in all children and in all instances; yet,
in clinical practice, management is frequently suboptimal. We investigated the attitude of Italian family pediatricians
towards the evaluation and treatment of different types of acute pain in children aged 7–12 years.
Methods: This is a cross-sectional study based on a 17-question survey accessible online from October 2017 to
October 2018. Responders had to describe cases of children suffering from any type of acute pain among headache,
sore throat, musculoskeletal/post-traumatic pain, and earache. Children’s characteristics, pain assessment modalities
and therapeutic approaches were queried. The following tests were used: Z-proportion to evaluate the distribution of
categorical data; chi-squared and Kruskall-Wallis to explore data heterogeneity across groups; Mann-Whitney for head-
to-head comparisons.
Results: Overall, 929 pediatricians presented 6335 cases uniformly distributed across the types examined. Pain was
more frequently of moderate intensity (42.2%, P < 0.001) and short duration (within some days: 98.4%, P < 0.001). Only
50.1% of responders used an algometric scale to measure pain and 60.5% always prescribed a treatment. In children
with mild-moderate pain (N = 4438), the most commonly used first-line non-opioids were ibuprofen (53.3%) and
acetaminophen (44.4%). Importantly, a non-recommended dosage was prescribed in only 5.3% of acetaminophen-
treated cases (overdosing). Among the misconceptions emerged, there were the following: i) ibuprofen and
acetaminophen have different efficacy and safety profiles (when choosing the non-opioid, effectiveness weighted
more for ibuprofen [79.7% vs 74.3%, P < 0.001] and tolerability for acetaminophen [74.0% vs 55.4%, P < 0.001]); ii)
ibuprofen must be taken after meals to prevent gastric toxicities (52.5%); ibuprofen and acetaminophen can be used
combined/alternated for persisting mild-moderate pain (16.1%). In case of moderate-severe pain not completely
controlled by opioids, ibuprofen and acetaminophen were the most used add-on medications, with ibuprofen being
much more prescribed than acetaminophen (65.2% vs 23.7%, respectively) overall and in all pain types.
Conclusions: Several gaps exist between the current practice of pain assessment and treatment and
recommendations. Further efforts are needed to raise awareness and improve education on the possible exposure of
the child to short- and long-term consequences in case of suboptimal pain management.
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Background
Pain is a very common symptom in children of all ages. It
is a multidimensional phenomenon characterized by sen-
sory, physiological, affective, cognitive, behavioral and
spiritual aspects and it is defined by the International
Association for the study of Pain as “an unpleasant sen-
sory and emotional experience associated with actual or
potential tissue damage, or described in terms of such
damage” [1]. Independently of the cause and patient age,
pain may weaken the physical and psychological integrity
of the child and cause stress to the parents; moreover, if
left untreated, it may exert short- and long-term effects,
including sensitization to pain episodes later in life [2, 3]:
for all these reasons, pain should be assessed and treated
in every patient [4–10].
Despite the availability of national and international
guidelines, in clinical practice pain remains often under-
recognized, under-evaluated and under-treated [11–19].
In Italy, the law 38/2010, concerning the right to access
palliative and pain care for all patients, has focused the
attention of pediatricians on the importance of consider-
ing the specific needs of children and their families
during the course of the disease. Consequently, many
initiatives have been undertaken to evaluate the prag-
matic approach to pain management in children, includ-
ing a number of meetings, courses, and surveys
promoted by the Federation of Italian Pediatricians. In
particular, in June 2011, a survey based on an anonym-
ous questionnaire aimed to evaluate the modalities of
pain assessment was sent online to 4900 family pediatri-
cians, and re-administered in February 2013 following a
3-day training-qualification course [20]. The results
showed increased awareness of insufficient pain assess-
ment in children after the course (from 47 to 53%), rele-
vant improvement in the practice of measuring and
reporting pain in medical records (from 58 to 74%), and
marked increase in the use of age-related algometric
scales (from 10 to 43%) [20]. However, although the
change in the attitude was remarkable, it was not suffi-
cient to ensure the optimal management of pain in the
pediatric population.
To provide an update on Italian family pediatricians’
attitude towards the assessment and treatment of acute
pain in school-aged children, a new survey was under-
taken in 2018. The aim of this study was to understand
the knowledge/misconceptions regarding the manage-
ment of different types of acute pain and to assess the
adherence of current practice to the available recom-
mendations and clinical evidence.
Methods
This is an Italian cross-sectional study based on a survey
conducted as part of a continuing medical education
(CME) course entitled “Acute Pain Management in
Pediatrics”. This distance learning course organized by
Edra (Milan, Italy), was accessible online between 25
October 2017 and 24 October 2018 and involved family
pediatricians. The CME course was promoted via a vou-
cher, in accordance with the CME regulation. Participa-
tion in the CME course was voluntary and completion
of the course and a positive result in the final test
allowed participants to obtain training credits.
The questionnaire, formulated by the authors of the
CME course (included among the authors of this article),
consisted of a total of 17 questions. All the answers were
mandatory and participants who wanted to complete the
CME course had to fill in at least two questionnaires for
each type of pain (headache, sore throat, musculoskeletal
and post-traumatic pain, and earache).
All questionnaires were completely anonymous and,
apart from the detailed information below, no personally
identifiable information was collected. The questionnaire
path varied according to the selected answers (see details
in the translated questionnaire in Additional file 1).
The survey included as first step the selection of the
type of pain, followed by 17 questions: to answer, the
pediatrician was asked to refer to a clinical scenario of a
child with acute pain managed in his/her daily practice.
Only children aged 7–12 years were considered. Ques-
tions 1–4 analyzed the characteristics of the pain (i.e. in-
tensity and duration) and the child demographics of the
cases described, questions 5–6 collected information on
pain assessment, and the remaining questions addressed
the therapeutic approach adopted in general (question
7), and for the management of the case presented (ques-
tions 8–17).
Data obtained from the answers were reported as
number and percentage (N, %) for categorical variables.
The answers expressed by scores were reported as mean,
median, standard deviation (SD) and interquartile range
(IQR). The Z-proportion test was used to evaluate the
distribution of categorical data. The chi-squared test and
Kruskall-Wallis test were used to evaluate the hetero-
geneity of data across groups. The Mann-Whitney test
was used for head-to-head comparisons. The P-value
was adjusted by means of the false discovery rate
method for multiple comparisons; P-values < 0.05 were
considered significant. All analyses were carried out
through software R version 3.5.2.
Results
Study participants
Overall, 929 pediatricians completed at least 1 question-
naire for a total of 6335 cases, with 777 physicians in-
cluding at least 8 cases. The main characteristics of
study participants are listed in Table 1.
A similar number of cases for each pain type was de-
scribed by responders: 1596 (25.2%) with headache, 1593
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(25.2%) with sore throat, 1546 (24.4%) with musculoskel-
etal or post-traumatic pain, and 1600 (25.2%) with
earache.
Survey results
Q1-Q4: characteristics of acute pain clinical scenarios
described in the questionnaires
Data on pain severity and duration and by pain type
(question 1 and 2) are shown in Table 2: pain was
significantly more frequently of moderate intensity (N =
2673, 42.2%, P < 0.001) and short duration (within some
days in 6231 [98.4%] cases, P < 0.001). Both intensity and
duration were significantly correlated with pain type
(P < 0.001, although for the duration of headache and
musculoskeletal pain the trend was not as clear as for
the other pain types).
Of the 6635 children with acute pain described by re-
sponders (question 3–4), 3487 (55%) were females, and
1383 (21.8%) were aged 7, 1444 (22.8%) 8, 938 (14.8%) 9,
1235 (19.5%) 10, 607 (9.6%) 11 and 728 (11.5) 12 year.
Q5-Q6: pain measurement
An algometric scale for pain measurement was used in
3174/6335 (50.1%) cases (Fig. 1a), and in most of them
(2440/3174, 76.9%) the pediatricians made this choice
because they felt that such tool must be used in every
patient with pain symptoms (Fig. 1b). In contrast, the
main reason for not employing an algometric scale was
that it should be applied only in children able to self-
assess pain (831/3161, 26.3%) or just occasionally (741/
3161, 23.4%) (Fig. 1c). An algometric scale was used
more frequently for measuring headache (54.8%, P <
0.001) and musculoskeletal pain or traumatic pain
(53.9%, P = 0.002), and less frequently for sore throat
(43.6%, P < 0.0001).
Q7-Q17: therapeutic approach
Next, participants were asked to indicate the main fac-
tors that, in general, drive their decision to treat
pediatric pain (question 7): 3831/6335 (60.5%) stated that
they always prescribe a treatment, as pain is a negative
experience for the child, whereas 1976/6335 (31.2%) de-
clared to prescribe an analgesic only for severe pain. An-
swers were similar by pain type.
The criteria rated as important/very important in the
decision to start an analgesic therapy (question 8) were
the impact of pain on the quality of life in 4990/6335
cases (78.8%) and pain intensity in 4845/6335 (76.5%),
followed by pain origin in 3851/6335 (60.8%) and dur-
ation in 3638/6335 (57.4%). The scores obtained were
compared by the Mann-Whitney test, which indicated a
Table 1 Main characteristics of participants
Total number 929
Gender
Males 295 (32)
Females 634 (68)
Age group, years
31–40 73 (7.9)
41–50 116 (12.5)
51–60 322 (34.6)
61–70 413 (44.5)
> 70 5 (0.5)
Geographical areaa
Northwest 211 (34.9)
Northeast 40 (6.6)
Centre 184 (30.5)
South 169 (28)
Questionnaires completed, median (range) 8 (1–17)
Data are expressed as frequencies (N [%]), unless otherwise specified
aGeographical area was not a mandatory field. % is calculated on 604
answers received
Table 2 Characteristics of acute pain clinical scenarios described in the questionnaires
Characteristic Type of pain Total
Headache
N = 1596
Sore throat
N = 1593
Musculoskeletal or
post-traumatic
N = 1546
Earache
N = 1600
P-value N = 6335
Intensity, N (%)
Mild 572 (35.8) 485 (30.5) 384 (24.8) 324 (20.3) < 0.001 1765 (27.9)
Moderate 674 (42.2) 701 (44.0) 679 (43.9) 619 (38.7) 2673 (42.2)
Severe 350 (22.0) 407 (25.5) 483 (31.3) 657 (41.9) 1897 (29.9)
Duration, N (%)
A few hours 700 (43.9) 344 (21.6) 458 (29.6) 875 (54.7) < 0.001 2377 (37.5)
1 day 373 (23.4) 593 (37.2) 414 (26.8) 472 (29.5) 1852 (29.2)
Some days 482 (30.2) 645 (40.5) 625 (40.4) 250 (15.6) 2002 (31.7)
At least 1 week 41 (2.5) 11 (0.7) 49 (3.2) 3 (0.2) 104 (1.6)
Data are expressed as frequencies (N [%])
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Fig. 1 a Cases in which an algometric scale was/was not used to measure pain, as a whole and by pain type. b Factors driving the choice of
using an algometric scale. c Factors driving the choice not to use an algometric scale
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statistically significant difference in terms of importance
for the impact on quality of life and pain intensity com-
pared to pain origin and duration; however, while the
difference was significant because of the big sample size,
the clinical relevance was low, due to the small magni-
tude of the difference among mean and median score
(data not shown).
Mild-moderate pain
In children with mild-moderate pain (question 9), the
general health status was deemed an important/very
important driver in the choice of the first-line non-
opioid molecule in 3067/4438 (69.1%) cases, followed by
age, possible comorbidities and concomitant therapies in
2346 (52.9%), 2288 (51.6%) and 2315 (52.1%),
respectively.
Overall, the active ingredients most frequently pre-
scribed as oral antalgic non-opioid therapy (question 10)
were ibuprofen in 2364/4438 (53.3%) cases and acet-
aminophen in 1972/4438 (44.4%) (Fig. 2a). Ketoprofen
lysine salt, naproxen and others were among the possible
answers: as they were used in 62 (1.4%) and 14 (0.3%)
and 26 (0.6%) of the cases described, respectively, data
on these agents were excluded. Ibuprofen was the most
frequently administered medication orally in case of
musculoskeletal/post-traumatic pain (64%), earache
Fig. 2 a Most frequently prescribed active ingredients, as a whole and by pain type. b Reasons driving prescription towards ibuprofen rather than
acetaminophen or another painkiller
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(58%) and sore throat (54%), whereas acetaminophen
was most commonly chosen for (treating) headache
(59%).
With regard to the dose regimen prescribed (question
11, Table 3), it was correct in all children treated with
ibuprofen and in 94.7% of those treated with acetamino-
phen; in the remaining cases (104/1972, 5.3%), the child
received a higher-than-recommended dose of acet-
aminophen (≥15mg/kg every 4–6 h).
Participants were then asked to rate by importance the
reasons for choosing acetaminophen vs ibuprofen as
preferred medication (question 10). For each reason, the
degree of importance (low [score 1–3] vs high [score 4–
5]) was similar between acetaminophen and ibuprofen:
efficacy, better tolerability, recommendations and com-
mon practice were assigned high importance, whereas
parental satisfaction/experience and history of asthma
were considered of low importance. For acetaminophen,
efficacy profile and good tolerability were equally rated
as the most important factors (1465/1972 [74.3%] and
1458/1972 [74.0%], respectively), followed by guideline
recommendations (N = 1231, 62.4%) and common prac-
tice (N = 1173, 59.5%). For ibuprofen, efficacy was the
most important factor in the vast majority of cases
(1885/2364 [79.7%]), followed by other recommenda-
tions, better tolerability and common practice (N = 1354
[57.3%], N = 1309 [55.4%] and N = 1251 [53.0%], respect-
ively). Parental satisfaction/experience was deemed less
important in 924 (46.9%) cases for acetaminophen and
in 967 (40.9%) cases for ibuprofen; similar figures were
seen for history of asthma (566 [28.7%]) and 527 (22.3%)
of cases, respectively).
As reported in Table 4, except for the efficacy profile,
that was significantly more relevant in the choice of ibu-
profen over acetaminophen, all the other reasons were
significantly more relevant in the choice of acetamino-
phen (chi-squared P-value ≤0.001): in particular, better
tolerability had a higher weight for 74.0% of pediatricians
who prescribed acetaminophen vs 55.4% of those choos-
ing ibuprofen.
In general, among the possible reasons to prefer ibu-
profen over acetaminophen or another painkiller (ques-
tion 13), the significantly more common were its higher
efficacy (961/2364, 40.7% P < 0.001) and the inflamma-
tory/infective origin of pain (925/2364, 39.1% P < 0.001)
(Fig. 2b).
In 1241 (52.5%) out of the 2364 clinical scenarios
treated with oral ibuprofen, pediatricians stated that they
advised to take this medication after meals (question 14)
because of the fear of gastric side effects; this was also
for 332 (14.0%) cases with persistent pain requiring
repeated administrations, for 184 (7.8%) cases on long-
term therapy and for 109 (4.6%) cases with previous
history of gastrointestinal discomfort. In contrast, the
prescription not to take ibuprofen after feeding was
made when the drug was administered only if needed in
498 (21.1%).
Overall, in the cases described in the questionnaires,
analgesic efficacy was the pharmacologic feature deemed
most important in the choice of the molecule prescribed
(in 2039/4438 cases, 45.9%) (Fig. 3), with no significant
differences by pain type (question 15).
Finally, in case of persistent mild-moderate pain (i.e.
only for pediatricians who had chosen the answers 1a,
2c or 2d), the therapeutic scheme most frequently
adopted for non-opioid analgesics (question 16) was
monotherapy repeated at regular intervals in 763/1512
(50.5%) cases or as needed in 397/1512 (26.3%; p < 0.001
for both) (Fig. 4). Notably, in 108 (7.1%) cases, ibuprofen
was used in combination with acetaminophen, and in
136 (9.0%) the two drugs were alternated. Similar results
were observed for all types of pain, except for headache,
for which monotherapy repeated as needed was
employed in 42% of cases, followed by monotherapy re-
peated at regular intervals in 32% of cases.
Moderate-severe pain
In case of moderate to severe pain not completely con-
trolled by opioid monotherapy, the agents most
Table 3 Dose regimens of ibuprofen and acetaminophen
Medication Posology N (%)
Ibuprofen, N = 2364 5 mg/kg every 6–8 h 912 (36.8)
10 mg/kg every 6–8 h 1452 (61.4)
Acetaminophen, N = 1972 10 mg/kg every 4–6 h 691 (35.0)
15 mg/kg every 4–6 h 1177 (59.7)
≥15mg/kg every 4–6 h 104 (5.3)
Data are expressed as frequencies (N [%])
Table 4 Criteria driving the choice toward ibuprofen or
acetaminophen in case of mild-moderate pain
Acetaminophen
N = 1972
Ibuprofen
N = 2364
Chi-squared
P-value
Effectiveness 1465 (74.3) 1885 (79.7) < 0.001
Better tolerability 1458 (74.0) 1309 (55.4) < 0.001
Recommendations
contained in the
guidelines
1231 (62.4) 1354 (57.3) 0.001
Established therapeutic
practice
1173 (59.5) 1251 (53.0) < 0.001
Parental satisfaction /
experience
924 (46.9) 967 (40.9) < 0.001
History of asthma 566 (28.7) 527 (22.3) < 0.001
Only answers rated of high importance (i.e. score 4 and 5) are presented. For
each drug, the reason(s) with a significantly higher weight in the choice (chi-
squared P-value) are highlighted in bold.
Data are expressed as frequencies (N [%]).
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frequently prescribed in combination with weak opioids
(question 17) were ibuprofen in 2980/4570 (65.2%) cases
and acetaminophen in 1084/4570 (23.7%); the data con-
sidered as a whole and by pain type are reported in Fig. 5.
Ibuprofen was the most frequent choice for all pain
types, whereas acetaminophen was more frequently pre-
scribed for headache, although less than ibuprofen
(37.0% vs 51.2%, respectively) (P < 0.001).
Discussion
Pediatric pain is an important public health problem,
even in apparently healthy subjects, due to both its
frequency and impact on daily living [19, 21]. The
risk to underestimate these aspects is high, owing in
part to the scarce use of appropriate assessment tools.
The present study provides information on the atti-
tude and practice of Italian family pediatricians in the
management of acute pain in children aged 7 to 12
years. The types of acute pain addressed in our ana-
lysis were equally distributed across headache, sore
throat, musculoskeletal/post-traumatic pain and ear-
ache, and were mostly of mild-moderate intensity and
short-lasting. Altogether, the survey highlighted a
poor adherence to current recommendations with re-
gard to the use of algometric scales for measuring
pain and to the treatment approach.
Fig. 3 Pharmacologic feature deemed as the most important in the choice of the non-opioid analgesic
Fig. 4 Therapeutic regimen of non-opioid analgesics prescribed to treat persistent mild-moderate pain
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National and International guidelines mandate the
measurement and relieve of pain in all children and in
all instances, as painful stimuli not adequately evaluated
and treated in the pediatric age may have important ef-
fects on the short- and long-term health outcome of
young patients [4, 6–8]. Optimal care requires assess-
ment of pain intensity through a psychometrically vali-
dated scale, along with the use of the most appropriate
medication and dosage for each individual patient. In
the present study, however, only half of participants de-
clared to employ an algometric scale to measure pain,
which were mainly used for headache and musculoskel-
etal pain, highlighting the urgent need to educate physi-
cians on the importance of using these tools. This
observation is alarming if one considers that the survey
was conducted more than 7 years after the Italian law
38/2010 had entered into force [22], and that several
promotional initiatives were carried out since then.
Among these, a survey targeting 4900 Italian family pe-
diatricians had shown that adequate training may help
increase the awareness on optimal management of pain
[20]: however, despite these efforts, the percentage of pe-
diatricians using an algometric scale in the present study
remained unchanged.
Regarding the therapeutic approach, 60.5% of the
participants stated that they always prescribe an anal-
gesic therapy because pain constitutes a negative ex-
perience for the child. This finding, together with the
observation that quality of life impairment and pain
intensity were the main reasons for deciding to start
a therapy, suggests a high sensitivity of the
pediatrician towards the negative physical as well as
emotional impact of pain, in line with the principles
of the Italian law 38/2010 [22]. However, nearly 1 in
3 pediatricians prescribed an analgesic drug only for
some types of pain, generally to avoid that the child
experiences intense pain, rather than for each in-
stance of pain.
National and International guidelines recommend
both ibuprofen or acetaminophen as first-line treatment
for acute pain with the same level of evidence, as they
have comparable efficacy and safety profile [4, 7, 23–25].
However, the similar efficacy of acetaminophen and ibu-
profen in musculoskeletal trauma, orthopedic pain and
headache is still insufficiently documented. Available evi-
dence supports ibuprofen as an adequate first-line op-
tion in the case of musculoskeletal trauma [26] and a
better analgesic compared to acetaminophen in this type
of pain [27] and headache as well (evidence from small
studies [28, 29]). In the management of sore throat and
earache, both ibuprofen and acetaminophen showed an
equivalent control of pain, even if ibuprofen could be
preferred because of its inflammatory properties [30]. In
the present study, ibuprofen and acetaminophen were
the most commonly used first-line non-opioid drugs in
case of mild-moderate pain, with a slight preference for
the former (53.3% vs 44.4%, respectively), in line with
the above studies [30–32].
One interesting finding regards the dosage prescribed
for both ibuprofen and acetaminophen: indeed, in all chil-
dren treated with ibuprofen and in 94.7% of those treated
with acetaminophen, the dosage was in line with current
recommendations, whereas in 5.3% of cases acetamino-
phen was overdosed [4]. Considering that in a previous
survey conducted among family pediatricians in Italy, only
13.5% of pediatricians had prescribed acetaminophen at
the correct dosage [20], our results are reassuring; still,
they pinpoint the need for further efforts to fully optimize
the management of pain in children also in light of the
fact that, in case of overdose, the toxicity of acetamino-
phen occurs quicker and is more difficult to manage as
compared with ibuprofen overdose [33]. This is likely due
Fig. 5 Analgesics used in combination with weak opioids to treat moderate-severe pain not completely controlled by monotherapy
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to the wider therapeutic window of ibuprofen compared
to that of acetaminophen [33, 34].
In case of mild-moderate pain, efficacy was the most
relevant aspect considered in the choice of ibuprofen,
which was preferred over acetaminophen or any other an-
algesic also for its anti-inflammatory activity. In contrast,
better tolerability was reported as more relevant when
prescribing acetaminophen, even though current evidence
and guidelines indicate that the safety profile of the two
drugs is similar, as no substantial differences in the inci-
dence of adverse events have been reported [30, 33].
Indeed, ibuprofen has a good safety profile in terms of
both gastric and renal tolerability similar to the profile
of acetaminophen [23, 24, 30, 33]. In one of the largest
trials of ibuprofen and acetaminophen, the risk of
gastrointestinal bleeding was low (7.2 per 100,000), with
no statistically significant difference between the two
treatment groups (p = 0.31) [30]. Other studies have
confirmed that upper gastrointestinal complications
(UGIC’s) are rare events in children treated with
NSAIDs, with a low absolute risk of about 2.4 UGIC in-
cidents per 10,000 children at emergency departments
([35]). Bianciotto and coworkers reported an adjusted
OR for the risk of UGICs in NSAID-treated children of
8.2 (95% CI 2.6–26.0), with one-third of cases attribut-
able to exposure to NSAIDs administered at therapeutic
doses [35]. However, no significant difference was found
in the risk of UGICs between acetaminophen and ibu-
profen (adjusted OR 2.0, 95% CI 1.5–2.6 and 3.7, 95% CI
2.3–5.9, respectively), although UGICs were lower in
children treated with acetaminophen [35]. In the present
study, as much as 52.5% of responders stated that they
had recommended to take ibuprofen after meals always
because of the fear of gastric side effects. However, it
must be kept in mind that the administration with food
slows the speed of absorption and may, thus, reduce effi-
cacy, possibly leading to more frequent administrations
and to the risk of over-dosing. For this reason, some au-
thors advise to take over-the-counter ibuprofen on a
fasting stomach to achieve a rapid onset of action and
effect, thereby avoiding the use of an ‘extra’ dose [33,
36–38]. The practice to take it after meals should be
limited to selected at-risk cases or in case of prolonged
administration.
As for the renal function, it has been shown that, in
children with normal function and effective circulating
volume, ibuprofen and acetaminophen are equally safe
and renal conditions are unlikely to occur [30, 33]. Cau-
tion is recommended in children with high dehydration
levels and pre-existing renal disease, since in these pa-
tients NSAIDs can be associated to an increased risk of
acute kidney injury even at the therapeutic doses [39,
40], as a result of NSAID-mediated inhibition of renal
prostaglandins [41]. In any case, keeping the patient
hydrated may help preventing dehydration and any kid-
ney toxicity.
On the other end, the concomitant administration of
the two molecules may increase the risk of renal toxicity
due to their synergistic effect on renal function [30]
(adjusted reporting odds ratios: 4.01 [95%CI: 2.96–5.43]
[42]). For this reason, the practice to combine or alter-
nate acetaminophen and ibuprofen must be discouraged
and avoided whenever not strictly necessary. On the
other hand, due to the ban on codeine and the FDA
black warning on the use of tramadol under 12 years of
age, the options of a family physician for the treatment
of a moderate-to-severe pain resistant to first-line
therapy are very limited, considering that the administra-
tion of a major opioid in this setting would be unlikely.
Some evidence from adult and pediatric literature sug-
gests that the association between acetaminophen and
ibuprofen is both efficacious and safe. Indeed, although
pediatricians should be fully aware of the potential risk
factors related to the concomitant use of acetaminophen
and ibuprofen, especially in case of dehydration, malnu-
trition, coexistent liver or gastric disease or administra-
tion of other drugs, the association of these two
medications maintains a reasonable cost-benefit ratio in
many situations of refractory pain. In this context, evi-
dence exists supporting the feasibility of the association
of the two drugs in some situations [43–45].
In the present survey, in case of mild-moderate pain
persisting for a few days or a week, monotherapy (either
repeated at regular intervals [50.5%] or as needed
[26.3%]) was the most frequently prescribed therapeutic
regimen. However, in 16.1% of cases ibuprofen and
acetaminophen were used in combination or alternated.
Despite the association could maintain a reasonable
cost-benefit ratio in some specific cases of non-
responding pain or fever, pediatricians must be fully
aware of the possible risk factors coming from the com-
bination of pathophysiological aspects of the two drugs
and that selecting the most suitable active substance for
the individual child may help optimizing the chance of
treatment success already upfront, thereby limiting the
need to administer further treatments. In this context,
parents and caregivers should receive clear indications
about the prescribed regimen.
Regarding the management of moderate-severe pain
not completely controlled by opioids, ibuprofen and
acetaminophen were the most used add-on medications,
with ibuprofen being much more prescribed than acet-
aminophen (65.2% vs 23.7%, respectively), overall and in
all pain types. This result is interesting, as ibuprofen and
acetaminophen have been shown to have less adverse
events than opioids in the treatment of acute pain in
children [25, 30] and, therefore, adding non-opioids to
opioid medications may help reducing the use and,
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hence, the toxicity of the latter. For this reason, in case of
moderate-severe pain, opioid medications should be added
to, rather than replace, non-opioids [25]. However, non-
opioids or opioids should always be used by taking into ac-
count their benefit/risk ratio profile. In this context, specific
cases must be considered, in whom the cause of pain may
depend on other rare conditions, such as headache related
to intracranial pressure or meningoencephalitis. Further-
more, it must be considered that even if non-opioids as ibu-
profen and acetaminophen are recommended as first-line
treatment, in some instances of sore throat or headache
caused by bacterial infections, antibiotic therapy must be
used following appropriate diagnosis.
Finally, one finding that deserves attention regards
some pharmacological characteristics not considered as
relevant by the responders when choosing a painkiller:
manageability (i.e. wide therapeutic window) [33] and
therapy compliance [46]. Compliance is a key element to
ensure the maximum efficacy of prescribed medications.
Among the factors that may affect therapy compliance
in pediatrics, the following are particularly important:
the pharmaceutical form, which varies according to the
child’s age, clinical characteristics and needs; drug palat-
ability, particularly important in the case of oral formu-
lations (which are the most appropriate for the children
described in the present study); dose volume and num-
ber of administrations per day, which should be limited
to make therapy more acceptable [46].
The current study has some limitations, which include
the cross-sectional design, the lack of validated questions
of the survey and a possible recall bias. We acknowledge
that pain was only measured by a conventional pain
scale. Owing to the multifactorial nature of this symp-
tom, a thorough assessment would require the evalu-
ation of a broad range of factors, which include physical,
social and school activities, psychological aspects, socio-
cultural contexts, family and peer interactions, cognitive
functioning, emotional distress, mood, behavior, and
pain-coping strategies [47]. Still, the tool for pain meas-
urement used in the study was selected and agreed upon
by all participating investigators. We know and under-
stand that any instrument used to measure pain can be
criticized. However, because to used tool is well vali-
dated and widely used in the literature, we are confident
that the results of pain assessment in our study are reli-
able and valid. The main strengths of our analysis are
the high number of participants and their homogeneous
distribution across Italy, which make the results of the
survey on pain management generalizable to the Italian
population of family pediatricians.
Conclusions
In the management of acute pain, current recommenda-
tions advocate the constant measurement of intensity
through algometric scales and the administration of ibu-
profen and acetaminophen as first line treatment. In this
context, the careful tailoring of the therapeutic strategy
is crucial to guarantee treatment compliance, ultimately
optimizing pain relief. The present survey revealed sev-
eral gaps between current practice and recommenda-
tions among Italian family pediatricians, with regard to
both assessment and therapeutic approaches of different
types of acute pain. Our results emphasize the need to
raise awareness on the possible exposure of the child to
an increased risk of adverse events and of short- and
long-term consequences in case of suboptimal pain
management. Although in the last decade several im-
provements have been achieved in Italy, further efforts
are required to provide children with the most adequate
care.
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